scholarly journals Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment

2005 ◽  
Vol 64 (11) ◽  
pp. 1665-1667 ◽  
Author(s):  
S N Nikas
Keyword(s):  
Psoriatic Arthritis ◽  
Skin Lesions ◽  
Immunosuppressive Drugs ◽  
Psoriatic Skin ◽  
Infliximab Treatment

scholarly journals Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis

2017 ◽  
Vol 9 (2) ◽  
pp. 26-29 ◽  
Author(s):  
Yuki Matsuura-Otsuki ◽  
Takaaki Hanafusa ◽  
Hiroo Yokozeki ◽  
Kyoko Watanabe
Keyword(s):  
Psoriatic Arthritis ◽  
Aseptic Meningitis ◽  
Joint Pain ◽  
Mononuclear Cells ◽  
Polymerase Chain Reaction Amplification ◽  
Skin Lesions ◽  
Psoriatic Skin ◽  
Infliximab Treatment ◽  
India Ink ◽  
Old Japanese

A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled. However, after 21 doses of infliximab, the skin lesions and joint pain exacerbated and became intractable. Ten days after the dosage of infliximab was increased, the patient experienced headache and nausea with high fever. He had scaly, well-circumscribed erythemas on his trunk, extremities, and deformed nails. He also had swelling and pain in multiple joints. His complete blood and differential leukocyte counts were normal. The level of C-reactive protein was 16.66 mg/dL, whereas anti-infliximab antibodies were absent. Nuchal rigidity was absent and there were no abnormal neurological findings; however, jolt test results were positive. Results from magnetic resonance imaging were normal, whereas those from cerebrospinal fluid (CSF) examination were almost normal. The CSF contained mononuclear cells and was negative for bacteriological cultures, India ink staining, and polymerase chain reaction amplification of herpesvirus group DNA. Headache and nausea improved 2 months after infliximab was discontinued. The patient failed to respond to infliximab treatment for PsA, and we diagnosed infliximab-induced aseptic meningitis. Infliximab was discontinued and treatment with ustekinumab and methotrexate was initiated. Thereafter, the psoriatic skin lesion and joint pain gradually improved. Infliximab-induced aseptic meningitis may be a differential diagnosis when symptoms of meningitis develop during infliximab administration.

Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab

2008 ◽  
Vol 33 (3) ◽  
pp. 321-325 ◽  
Author(s):  
J. Borrás-Blasco ◽  
A. Gracia-Perez ◽  
C. Nuñez-Cornejo ◽  
J. D. Rosique-Robles ◽  
A. Mateu-Puchades ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Skin Lesions ◽  
Psoriatic Skin

scholarly journals Psoriatic onycho-pachydermo-periostitis / Psoriatični onihopahidermoperiostitis

2010 ◽  
Vol 2 (2) ◽  
pp. 54-58
Author(s):  
Zorica Perić-Hajzler ◽  
Lidija Kandolf-Sekulović ◽  
Lidija Zolotarevski
Keyword(s):  
Psoriatic Arthritis ◽  
Antibody Therapy ◽  
Skin Lesions ◽  
Treatment Modalities ◽  
Psoriatic Skin ◽  
Symptom Improvement ◽  
Nail Changes ◽  
The Family ◽  
History Of ◽  
Inflammatory Drugs

Abstract Psoriatic onycho-pachydermo-periostitis has been recognized as an uncommon subset of psoriatic arthritis, and to date, only a few cases have been reported. In general, psoriatic onycho-pachydermo-periostitis is regarded as a unique variant of psoriatic arthritis, but its pathology and pathophysiology are not well understood. Although psoriatic onychopachydermo- periostitis is usually found in patients with psoriasis, it can also be found in patients without psoriatic skin lesions. It is characterized by psoriatic nail changes (usually onycholysis), painful swelling of the soft tissue close to the distal phalanges, and radiographic changes of the distal phalanges with periosteal reaction and bone erosions. We present a 58-year-old man with a 3-year history of deformation, thickened nails and pustules on the skin of his fingers and toes, and painful redness of the nail bed accompanied with pain in small joints. The family history was negative. After confirmation of the diagnosis, methotrexate: 15 mg weekly, was initiated which led to symptoms improvement. Treatment of psoriatic onycho-pachydermo-periostitis is difficult. It is based on treatment modalities used for other forms of psoriatic arthritis, such as sulphasalazine, methotrexate, and anti-tumor necrosis factor antibody therapy with adalimumab and etanercept. Nonsteroidal anti-inflammatory drugs are usually ineffective. Retinoids, subungual cyclosporine and corticosteroid therapy also showed inefficient. In our patient, methotrexate has shown efficacy in symptom improvement.

scholarly journals The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice

2019 ◽  
Vol 57 (3) ◽  
pp. 299-306
Author(s):  
E. Yu. Loginova ◽  
Yu. L. Korsakova ◽  
A. D. Koltakova ◽  
E. E. Gubar ◽  
P. L. Karpova ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Skin Lesions ◽  
Tender Joint Count ◽  
Psoriatic Skin ◽  
Efficacy And Safety ◽  
Tender Joint ◽  
Number Of Patients ◽  
Conventional Dmards ◽  
Low Activity

Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying antirheumatic drug (DMARD) apremilast (AP; Otesla®) in patients with active psoriatic arthritis (PsA) at 14 and 26 weeks after starting the treatment and to identify the place of AP in the combination therapy of patients with PsA, by taking into consideration a comorbidity.Subjects and methods. Examinations were made in 20 patients (11 women and 9 men) with active PsA who had comorbidity, lack of efficiency of or intolerance to previous therapy with synthetic DMARDs or biologic agents, and contraindications to its use. The median baseline Disease Activity in Psoriatic Arthritis (DAPSA) score was 35.6 [24.8; 55.6]; those of DAS and DAS28 were 3.8 [3.2; 5.0] and 4.4 [4.0; 5.2], respectively. AP (Otesla®) was administered in tablets with a starting dose of 10 mg/day with a daily dose escalation of 10 mg to the therapeutic dose of 60 mg/day for 26 weeks. At baseline, 14 and 26 weeks, the disease activity and efficiency of AP were evaluated using DAPSA, DAS, and DAS28, as well as minimal disease activity (MDA) criteria (tender joint count ≤1; swollen joint count ≤1; PASI ≤1 or BSA ≤3%; a patient’s assessment of pain ≤15 mm; patient’s global assessment ≤ 20 mm; Health Assessment Questionnaire (HAQ) ≤ 0.5; enthesitis ≤1). The investigators estimated the number of patients who had achieved remission (DAPSA≤4; DAS<1.6; DAS28<2.6), low activity (5≤DAPSA≤14; 1.6≤DAS<2.4; 2.6≤DAS28<3.2) or MDA (5 of the 7 criteria) during AP therapy at 26-week follow-up. The safety of therapy was evaluated, by analyzing the adverse events (AE): the frequency, severity, and time of their occurrence were studied.Results and discussion. At 26 weeks after AP therapy initiation, there was a significant decrease of all PsA activity scores as compared to the baseline ones to the following median values: DAPSA 25.9 [11.3; 35.2]; DAS 3.3 [1.8; 3.9], and DAS28 3.4 [2.3; 4.8]. The median BASDAI and ASDAS scores also significantly declined from 5.1 [2.5; 7.3] and 3.35 [2.3; 4.2] to 3.45 [2.15; 6.15] and 2.7 [1.8; 3.35], respectively. The median area of psoriatic skin lesions (body surface area (BSA)) significantly reduced from 2 [0.35; 6] to 1 [0.2; 2]. At 26 weeks after starting AP therapy, the low activity/remission according to DAPSA, DAS, and DAS28 was achieved by 20/10%, 20/15%, and 10/35% of patients, respectively. Three (15%) patients achieved MDA. Fifteen (75%) of the 20 patients completed an AP therapy course. In the period of 14 to 26 weeks, four patients dropped out of the study due to ineffective therapy and one because of a severe AE (pneumonia at 14 weeks of treatment); at 26 weeks, another patient was withdrawn due to lack of effect. At 14 weeks, ten patients had a moderate AE that did not required treatment discontinuation. The most common AE were diarrhea in 5 (25%) patients, headache in 4 (20%), nausea in 3 (15%), and insomnia in 3 (15%).Conclusion. AP is a safe and effective drug for the treatment of PsA patients with moderate and high inflammatory activity and various comorbidities that do not allow the use of conventional DMARDs.

THU0455 Evaluating Psoriatic Skin Lesions in Psoriasis and Psoriatic Arthritis: Ultrasound as A Complementary Measure

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 356.2-357 ◽  
Author(s):  
Y. Kisten ◽  
E. af Klint ◽  
N. Györi ◽  
H. Rezaei ◽  
L. Eidsmo ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Skin Lesions ◽  
Psoriatic Skin

Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis

2009 ◽  
Vol 36 (1) ◽  
pp. 137-140 ◽  
Author(s):  
PROTON RAHMAN ◽  
ROBERT D. INMAN ◽  
WALTER P. MAKSYMOWYCH ◽  
JEFF P. REEVE ◽  
LYNETTE PEDDLE ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Permutation Test ◽  
Psoriatic Skin ◽  
Nucleotide Polymorphisms ◽  
Marker Haplotype ◽  
Sliding Windows ◽  
Genome Wide ◽  
Canadian Population ◽  
Interleukin 23 ◽  
Coding Snp

Objective.A recent genome-wide pooling study noted a significant association of interleukin 23 receptor (IL-23R) and psoriasis. Overxpression of IL-23 has been detected in lesional psoriatic skin, and induces epidermal proliferation. Given the interplay between psoriasis and PsA, we examined the association of IL-23R variants in 2 independent Canadian Caucasian cohorts of patients with psoriatic arthritis (PsA).Methods.We examined 496 PsA probands and 476 controls. Cases and controls were genotyped for a panel of 11 single-nucleotide polymorphisms (SNP) in IL-23R. Allele and haplotype associations were calculated using WHAP software. P values for haplotype associations were calculated using a permutation test.Results.The 381Gln allele of the coding SNP Arg381Gln (rs11209026) was found to be protective in the Canadian population (p = 0.004; corrected p = 0.044).A 2-marker haplotype from SNP rs7530511 and rs11209026 was associated with PsA (p = 0.011). All 3-marker sliding windows containing SNP rs11209026 were associated with PsA (p = 0.02 for all 3 windows). The magnitude of effect of IL-23R association in PsA appears to be similar to that reported in uncomplicated psoriasis.Conclusion.Significant associations between Arg381Gln SNP and haplotypes encoding this variant were noted in PsA. It remains to be determined what contribution of this association, if any, is specifically due to the inflammatory arthritis (PsA) rather than psoriasis.

Activated and cycling lymphocytes in benign dermal lymphocytic infiltrates including psoriatic skin lesions

1985 ◽  
Vol 278 (2) ◽  
pp. 92-96 ◽  
Author(s):  
G. Lange Wantzin ◽  
J. K. Larsen ◽  
I. J. Christensen ◽  
E. Ralfkiaer ◽  
M. Tjalve ◽  
...  
Keyword(s):  
Skin Lesions ◽  
Psoriatic Skin ◽  
Lymphocytic Infiltrates

Psoriatic skin lesions induced by abatacept: Case report and review of the published work

2016 ◽  
Vol 44 (7) ◽  
pp. 845-846 ◽  
Author(s):  
Ikuko Ueda-Hayakawa ◽  
Chuyen Nguyen Thi Hong ◽  
Yoko Ueki ◽  
Naotomo Kambe ◽  
Hiroyuki Okamoto
Keyword(s):  
Case Report ◽  
Skin Lesions ◽  
Psoriatic Skin

Ankylosing spondylitis, other spondyloarthritides, and related conditions

2010 ◽  
pp. 3603-3616 ◽  
Author(s):  
J. Braun ◽  
J. Sieper
Keyword(s):  
Rheumatoid Arthritis ◽  
Back Pain ◽  
Ankylosing Spondylitis ◽  
Gastrointestinal Tract ◽  
Rheumatic Diseases ◽  
Skin Lesions ◽  
Inflammatory Back Pain ◽  
Psoriatic Skin ◽  
Inflammatory Rheumatic Diseases ◽  
History Of

The spondyloarthritides are a group of inflammatory rheumatic diseases with predominant involvement of axial and peripheral joints and entheses, together with other characteristic clinical features, including inflammatory back pain, sacroiliitis, peripheral arthritis (mainly in the legs), enthesitis, dactylitis, preceding infection of the urogenital/gastrointestinal tract, psoriatic skin lesions, Crohn-like gut lesions, anterior uveitis, and a family history of Spondyloarthritis. They are the second most frequent inflammatory rheumatic diseases after rheumatoid arthritis....

scholarly journals Psoriatic arthritis with skin lesions localized to the scalp: A case report

2020 ◽  
Vol 21 (6) ◽  
pp. 264-267
Author(s):  
Tetsuya Akaishi ◽  
Kenshi Yamasaki ◽  
Yu Mori ◽  
Toshiya Takahashi ◽  
Takuya Izumiyama ◽  
...  
Keyword(s):  
Case Report ◽  
Psoriatic Arthritis ◽  
Skin Lesions
Sign in / Sign up

Export Citation Format

Share Document